Welcome!

News Feed Item

NeuroRx Provides Clinical Development Update for Cyclurad(TM), a Novel Treatment for Acute Suicidal Crisis in Bipolar Disorder

IND for Phase II/III Trial of Cyclurad to Be Filed in Q1 2016; Manufacturing Agreement in Place to Support Study; NeuroRx Announces Key Personnel Additions to Support Cyclurad Development

WILMINGTON, DE -- (Marketwired) -- 12/16/15 -- NeuroRx, a clinical stage pharmaceutical company developing novel therapeutics for the treatment of central nervous system disorders, today announced its plans for advancing Cyclurad™, the company's lead drug candidate, into a Phase II/III clinical trial for the treatment of acute suicidal crisis associated with bipolar depression. The company intends to file an investigational new drug (IND) application with the United States Food and Drug Administration (FDA) for the planned study in the first quarter of 2016 and expects to initiate the trial during the first half of 2016. In preparation for the planned clinical trial initiation, NeuroRx has established a partnership with WuXi Apptec through which WuXi will formulate and manufacture the Cyclurad required for the study. Additionally, the Company is in the final stages of selecting a contract research organization for the Phase II/III trial.

"There is a clear and urgent need for an effective treatment for acute suicidal crisis in bipolar depression, which according to the World Health Organization claims the lives of more than 2,100 individuals around the world each day. We believe that clinical data generated to date on the combination of ketamine and Cyclurad's drug components, while still in proof of concept stage, suggest that NeuroRx's approach can potentially prolong the well-established therapeutic impact of ketamine without the negative side effects in suicidal bipolar patients," said Professor Daniel Javitt, M.D., Ph.D., who chairs NeuroRx's scientific advisory board.

"It is also important to note that D-cycloserine, one of the active ingredients in Cyclurad, has been identified by the American Psychiatric Association Task Force on Novel Biomarkers and Therapeutics as one of the most promising clinical-stage drugs for treating depression by modulating the NMDA receptor. With these considerations in mind, we have a singular focus on advancing the development of Cyclurad, the first oral therapeutic for the treatment of suicidal crisis associated with bipolar disorder, as rapidly as possible. We anticipate initiating our planned Phase II/III trial in the coming year," said Jonathan Javitt, M.D., chief executive officer of NeuroRx.

In additional corporate news, NeuroRx today announced the appointment of several highly-regarded pharmaceutical industry leaders to key board and management team positions. Each of these experts is expected to contribute significantly to the ongoing clinical advancement of Cyclurad. These appointments include:

Hon. Sherry A Glied, Ph.D., Board of Directors

Dr. Glied, whose principal areas of research are in health policy reform and mental health care policy, was named Dean of New York University's Robert F. Wagner Graduate School of Public Service in 2013. From 1989-2013, Dr. Glied was professor of health policy and management at Columbia University's Mailman School of Public Health and served as chair of the department of health policy and management from 1998-2009. In 2010, Dr. Glied was confirmed by the U.S. Senate as Assistant Secretary for Planning and Evaluation at the Department of Health and Human Services, serving in that capacity from July 2010 through August 2012. She had previously served as senior economist for health care and labor market policy on the President's Council of Economic Advisers in 1992-1993, under Presidents Bush and Clinton, and participated in the Clinton Health Care Task Force.

Philip T. Lavin, Ph.D., Chief Methodologist

Dr. Lavin is a highly-respected biostatistician with more than 30 years of experience supporting the design and analysis of clinical trials. Previously, he was a member of the biostatistics faculty at the Harvard School of Public Health and a member of the Department of Surgery at Harvard Medical School where he was affiliated for over 25 years. He co-founded Boston Biostatistics in 1983, a company now known as Aptiv Solutions. During his career, Dr. Lavin has served as lead biostatistician for 50 FDA approvals, including 38 PMAs, more to date than any other biostatistician. He has also served as a Special Government Employee for 30 years where he has advised FDA on complex statistical and policy issues.

Richard C. Siegel, Ph.D., Executive Vice President of Drug Development and Manufacture

Dr. Siegel brings extensive expertise in both technical and strategic aspects of early and late stage drug development. His experience includes process development and manufacture of small molecule drugs, monoclonal antibodies, therapeutic proteins and conjugates, peptides, cellular products and oligonucleotides. During his career, Dr. Siegel has held a number of high-level drug development and manufacturer positions within the Johnson & Johnson family of companies. These include Vice President of R&D and Global Head of Portfolio Management at Janssen Research and Development.

About Bipolar Depression and Acute Suicidal Crisis

Bipolar depression is a lethal disease affecting three million Americans. Approximately 100 Americans and more than 2,100 people worldwide with this condition end their lives each day. Although only 10% of the 30 million Americans suffering with depressive disorders have bipolar disorder, patients with bipolar disorder account for 67% of all associated suicides. Those with acute suicidal crisis, as classified by FDA-recognized scales, have a 33% chance of death within six months of onset. Despite the nature of acute suicidal crisis, many patients seek medical care or are brought to care by families and physicians. Yet, there is no currently approved therapy for the treatment of acute suicidal crisis and most commonly used antidepressants bear an FDA-mandated warning label identifying the potential to trigger suicide.

About Cyclurad™

Cyclurad™ is being developed as a rapid-onset and sustained treatment for acute suicidal crisis associated with bipolar depression. Cyclurad combines D-cycloserine, an N-methyl-D-aspartate (NMDA) receptor modulator; and lurasidone, a 5-HT2a receptor antagonist. NeuroRx's investigational treatment approach begins with a single dose of ketamine, an FDA approved anesthetic, followed by approximately six weeks of daily oral Cyclurad. Peer-reviewed and published results from two Phase II clinical studies demonstrate a significant decline in symptoms of depression following administration of D-cycloserine. Findings from one of these studies found that bipolar patients who were already receiving a 5-HT2a antagonist demonstrated more than a 50% reduction in symptoms of depression and a 75% reduction in suicidal ideation when ketamine and D-cycloserine were added to their treatment regimen. Cyclurad is being developed as a convenient, oral, fixed-dose combination of an 5-HT2a antagonist and D-cycloserine, to be administered following a single dose of ketamine.

About NeuroRx, Inc.

NeuroRx, Inc. is a clinical stage pharmaceutical company that is developing Cyclurad™, the first oral therapeutic for the treatment of suicidal crisis associated with bipolar disorder. The company is built upon 30 years of basic science and clinical expertise in understanding the role of the brain's N-methyl-D-aspartate (NMDA) receptor in regulating human thought processes in general and in regulating depression and suicidality in specific. NeuroRx expects to initiate a Phase II/III clinical trial of Cyclurad in combination with ketamine for the treatment of acute suicidal crisis in bipolar depression during the first half of 2015. More information at www.neurorxpharma.com

Contacts:

Stephanie Diaz (Investors)
Vida Strategic Partners
415-675-7401
Email Contact

Tim Brons (Media)
Vida Strategic Partners
415-675-7402
Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
As you know, enterprise IT conversation over the past year have often centered upon the open-source Kubernetes container orchestration system. In fact, Kubernetes has emerged as the key technology -- and even primary platform -- of cloud migrations for a wide variety of organizations. Kubernetes is critical to forward-looking enterprises that continue to push their IT infrastructures toward maximum functionality, scalability, and flexibility. As they do so, IT professionals are also embr...
Docker and Kubernetes are key elements of modern cloud native deployment automations. After building your microservices, common practice is to create docker images and create YAML files to automate the deployment with Docker and Kubernetes. Writing these YAMLs, Dockerfile descriptors are really painful and error prone.Ballerina is a new cloud-native programing language which understands the architecture around it - the compiler is environment aware of microservices directly deployable into infra...
Apptio fuels digital business transformation. Technology leaders use Apptio's machine learning to analyze and plan their technology spend so they can invest in products that increase the speed of business and deliver innovation. With Apptio, they translate raw costs, utilization, and billing data into business-centric views that help their organization optimize spending, plan strategically, and drive digital strategy that funds growth of the business. Technology leaders can gather instant recomm...
In an age of borderless networks, security for the cloud and security for the corporate network can no longer be separated. Security teams are now presented with the challenge of monitoring and controlling access to these cloud environments, at the same time that developers quickly spin up new cloud instances and executives push forwards new initiatives. The vulnerabilities created by migration to the cloud, such as misconfigurations and compromised credentials, require that security teams t...
Blockchain has shifted from hype to reality across many industries including Financial Services, Supply Chain, Retail, Healthcare and Government. While traditional tech and crypto organizations are generally male dominated, women have embraced blockchain technology from its inception. This is no more evident than at companies where women occupy many of the blockchain roles and leadership positions. Join this panel to hear three women in blockchain share their experience and their POV on the futu...
Serverless Architecture is the new paradigm shift in cloud application development. It has potential to take the fundamental benefit of cloud platform leverage to another level. "Focus on your application code, not the infrastructure" All the leading cloud platform provide services to implement Serverless architecture : AWS Lambda, Azure Functions, Google Cloud Functions, IBM Openwhisk, Oracle Fn Project.
DevOps is often described as a combination of technology and culture. Without both, DevOps isn't complete. However, applying the culture to outdated technology is a recipe for disaster; as response times grow and connections between teams are delayed by technology, the culture will die. A Nutanix Enterprise Cloud has many benefits that provide the needed base for a true DevOps paradigm. In their Day 3 Keynote at 20th Cloud Expo, Chris Brown, a Solutions Marketing Manager at Nutanix, and Mark Lav...
AI and machine learning disruption for Enterprises started happening in the areas such as IT operations management (ITOPs) and Cloud management and SaaS apps. In 2019 CIOs will see disruptive solutions for Cloud & Devops, AI/ML driven IT Ops and Cloud Ops. Customers want AI-driven multi-cloud operations for monitoring, detection, prevention of disruptions. Disruptions cause revenue loss, unhappy users, impacts brand reputation etc.
The platform combines the strengths of Singtel's extensive, intelligent network capabilities with Microsoft's cloud expertise to create a unique solution that sets new standards for IoT applications," said Mr Diomedes Kastanis, Head of IoT at Singtel. "Our solution provides speed, transparency and flexibility, paving the way for a more pervasive use of IoT to accelerate enterprises' digitalisation efforts. AI-powered intelligent connectivity over Microsoft Azure will be the fastest connected pat...
Serverless Computing or Functions as a Service (FaaS) is gaining momentum. Amazon is fueling the innovation by expanding Lambda to edge devices and content distribution network. IBM, Microsoft, and Google have their own FaaS offerings in the public cloud. There are over half-a-dozen open source serverless projects that are getting the attention of developers.
CloudEXPO has been the M&A capital for Cloud companies for more than a decade with memorable acquisition news stories which came out of CloudEXPO expo floor. DevOpsSUMMIT New York faculty member Greg Bledsoe shared his views on IBM's Red Hat acquisition live from NASDAQ floor. Acquisition news was announced during CloudEXPO New York which took place November 12-13, 2019 in New York City.
As you know, enterprise IT conversation over the past year have often centered upon the open-source Kubernetes container orchestration system. In fact, Kubernetes has emerged as the key technology -- and even primary platform -- of cloud migrations for a wide variety of organizations. Kubernetes is critical to forward-looking enterprises that continue to push their IT infrastructures toward maximum functionality, scalability, and flexibility. As they do so, IT professionals are also embr...
BMC has unmatched experience in IT management, supporting 92 of the Forbes Global 100, and earning recognition as an ITSM Gartner Magic Quadrant Leader for five years running. Our solutions offer speed, agility, and efficiency to tackle business challenges in the areas of service management, automation, operations, and the mainframe.
The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to wait for long development cycles that produce software that is obsolete at launch. DevOps may be disruptive, but it is essential. DevOpsSUMMIT at CloudEXPO expands the DevOps community, enable a wide sharing of knowledge, and educate delegates and technology providers alike.
According to the IDC InfoBrief, Sponsored by Nutanix, “Surviving and Thriving in a Multi-cloud World,” multicloud deployments are now the norm for enterprise organizations – less than 30% of customers report using single cloud environments. Most customers leverage different cloud platforms across multiple service providers. The interoperability of data and applications between these varied cloud environments is growing in importance and yet access to hybrid cloud capabilities where a single appl...